Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $11.01 and traded as high as $11.80. Keros Therapeutics shares last traded at $11.31, with a volume of 423,104 shares changing hands.
Wall Street Analyst Weigh In
KROS has been the subject of several analyst reports. Leerink Partners reduced their target price on Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating for the company in a report on Tuesday, August 4th. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Keros Therapeutics in a report on Tuesday, August 4th. Wells Fargo & Company dropped their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Keros Therapeutics in a research report on Tuesday, November 10th. Finally, Wall Street Zen upgraded shares of Keros Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, November 9th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $20.00.
View Our Latest Research Report on KROS
Keros Therapeutics Stock Up 12.8%
The company has a 50-day moving average price of $11.01 and a 200-day moving average price of $11.62. The company has a market capitalization of $221.90 million, a price-to-earnings ratio of -4.01 and a beta of 1.13.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of ($0.96) by $1.66. Keros Therapeutics had a negative return on equity of 21.85% and a negative net margin of 256.60%. The business had revenue of $40.01 million during the quarter, compared to analysts' expectations of $14.76 million. Equities analysts expect that Keros Therapeutics, Inc. will post -3.73 EPS for the current fiscal year.
Keros Therapeutics announced that its board has initiated a share buyback plan on Wednesday, September 9th that allows the company to buy back $5 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 2.3% of its stock through open market purchases. Share repurchase plans are typically an indication that the company's management believes its shares are undervalued.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. raised its stake in Keros Therapeutics by 42.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 254,099 shares of the company's stock valued at $2,897,000 after purchasing an additional 76,253 shares during the last quarter. Jump Financial LLC boosted its holdings in Keros Therapeutics by 239.0% in the 3rd quarter. Jump Financial LLC now owns 52,204 shares of the company's stock valued at $595,000 after purchasing an additional 36,804 shares during the period. Marshall Wace LLP boosted its holdings in Keros Therapeutics by 234.6% in the 3rd quarter. Marshall Wace LLP now owns 115,770 shares of the company's stock valued at $1,320,000 after purchasing an additional 81,170 shares during the period. Nantahala Capital Management LLC grew its position in Keros Therapeutics by 5.6% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,490,051 shares of the company's stock worth $16,987,000 after purchasing an additional 79,632 shares during the last quarter. Finally, Diversified Trust Co acquired a new stake in Keros Therapeutics in the 3rd quarter worth $133,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.
Keros Therapeutics Company Profile
(
Get Free Report)
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions by modulating signaling pathways in the transforming growth factor beta (TGF-β) protein family. Its research has centered on disorders involving blood-cell production and muscle function. The company's pipeline has included elritercept, an investigational therapy designed to address anemia and other complications associated with blood disorders, as well as candidates developed for muscle-related conditions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.